841 related articles for article (PubMed ID: 24837095)
21. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness.
Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A
Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684
[TBL] [Abstract][Full Text] [Related]
22. Gatekeeper Mutations and Intratumoral Heterogeneity in
Smyth EC; Babina IS; Turner NC
Cancer Discov; 2017 Mar; 7(3):248-249. PubMed ID: 28264865
[TBL] [Abstract][Full Text] [Related]
23. Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas.
Zen Y; Fujii T; Itatsu K; Nakamura K; Minato H; Kasashima S; Kurumaya H; Katayanagi K; Kawashima A; Masuda S; Niwa H; Mitsui T; Asada Y; Miura S; Ohta T; Nakanuma Y
Hepatology; 2006 Nov; 44(5):1333-43. PubMed ID: 17058219
[TBL] [Abstract][Full Text] [Related]
24. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
[TBL] [Abstract][Full Text] [Related]
25. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.
Sia D; Losic B; Moeini A; Cabellos L; Hao K; Revill K; Bonal D; Miltiadous O; Zhang Z; Hoshida Y; Cornella H; Castillo-Martin M; Pinyol R; Kasai Y; Roayaie S; Thung SN; Fuster J; Schwartz ME; Waxman S; Cordon-Cardo C; Schadt E; Mazzaferro V; Llovet JM
Nat Commun; 2015 Jan; 6():6087. PubMed ID: 25608663
[TBL] [Abstract][Full Text] [Related]
26. Comparative clinicopathological study of biliary intraductal papillary neoplasms and papillary cholangiocarcinomas.
Fujikura K; Fukumoto T; Ajiki T; Otani K; Kanzawa M; Akita M; Kido M; Ku Y; Itoh T; Zen Y
Histopathology; 2016 Dec; 69(6):950-961. PubMed ID: 27410028
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Lowery MA; Ptashkin R; Jordan E; Berger MF; Zehir A; Capanu M; Kemeny NE; O'Reilly EM; El-Dika I; Jarnagin WR; Harding JJ; D'Angelica MI; Cercek A; Hechtman JF; Solit DB; Schultz N; Hyman DM; Klimstra DS; Saltz LB; Abou-Alfa GK
Clin Cancer Res; 2018 Sep; 24(17):4154-4161. PubMed ID: 29848569
[No Abstract] [Full Text] [Related]
28. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
29. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion.
Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Kato A; Yoshitomi H; Furukawa K; Takeuchi D; Takayashiki T; Suda K; Takano S; Kondo Y; Miyazaki M
Am J Surg Pathol; 2011 Apr; 35(4):512-21. PubMed ID: 21412069
[TBL] [Abstract][Full Text] [Related]
30. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
[TBL] [Abstract][Full Text] [Related]
31. Infigratinib in patients with advanced cholangiocarcinoma with
Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
[TBL] [Abstract][Full Text] [Related]
32. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
[TBL] [Abstract][Full Text] [Related]
33. Rare Incidence of
Lim SM; Yoo JE; Lim KH; Meng Tai DW; Cho BC; Park YN
Cancer Res Treat; 2017 Jan; 49(1):185-192. PubMed ID: 27121721
[TBL] [Abstract][Full Text] [Related]
34. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
[TBL] [Abstract][Full Text] [Related]
35. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
[TBL] [Abstract][Full Text] [Related]
36. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
37. Futibatinib for
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
[TBL] [Abstract][Full Text] [Related]
38. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
39. Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.
Riener MO; Vogetseder A; Pestalozzi BC; Clavien PA; Probst-Hensch N; Kristiansen G; Jochum W
Hum Pathol; 2010 Nov; 41(11):1558-65. PubMed ID: 20621328
[TBL] [Abstract][Full Text] [Related]
40. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]